A citizen receiving the Pfizer vaccine injection. [Image source=Yonhap News]

A citizen receiving the Pfizer vaccine injection. [Image source=Yonhap News]

View original image


[Asia Economy Yeongnam Reporting Headquarters Reporter Kim Yong-woo] In Ulsan, a man in his 40s working at a large corporation died three days after receiving the Pfizer vaccine.


According to Ulsan city health authorities on the 16th, employee A of a major corporation died while receiving inpatient treatment at a hospital that day.


A received the second dose of the Pfizer vaccine at the company clinic on the 13th, and from the next day experienced symptoms of difficulty breathing and was transported to the emergency room. He was later reported to have fallen into an unconscious state.


It was confirmed that A had underlying health conditions.


A health official stated, “We plan to investigate the correlation with the vaccine.”


According to the COVID-19 Vaccination Response Promotion Team as of the 15th, since the start of vaccinations in Korea on February 26, a total of 227,232 suspected adverse reaction cases have been reported.


The current adverse reaction reporting rates per vaccine dose administered are Janssen 0.60%, Moderna 0.56%, AstraZeneca 0.50%, and Pfizer 0.35%.


The total number of reported deaths is 615, broken down by vaccine type as follows: Pfizer 325, AstraZeneca 267, Moderna 12, and Janssen 11.


The health authorities urged, “If symptoms suspected of myocarditis or pericarditis appear after vaccination, prompt medical consultation is necessary.”


Symptoms suspected of myocarditis or pericarditis include ▲chest pain, pressure, or discomfort ▲difficulty breathing, shortness of breath, or pain when breathing ▲rapid or irregular heartbeat ▲fainting, among others.



Additionally, although rare, some vaccines may cause thrombocytopenic thrombosis or Guillain-Barr? syndrome after vaccination.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing